Hodgkin’s Lymphoma Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Hodgkin’s Lymphoma” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The publisher estimates that in 2019, there were 80,800 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.
• In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.
• The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/TNFRSF8, microtubules (tubulin), DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.
• The greatest proportion of the industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
• Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral, intratumoral, and subcutaneous formulations.
• The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
• The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.
• The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
• Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 51 trials.
• Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin’s lymphoma, followed by Bristol Myers Squibb.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Subtypes

TREATMENT

• Chemotherapy
• Radiation therapy
• Immunotherapy
• Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• AFM13 for Hodgkin’s Lymphoma (April 9, 2021)
• Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020)
• Keytruda for Hodgkin’s Lymphoma (May 13, 2020)
• Keytruda for Hodgkin’s Lymphoma (March 2, 2020)

KEY REGULATORY EVENTS

• New Approvals, Biosecurity In Spotlight As China Gears For National Congress

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Daiichi’s Novel EZH Candidate Progresses In New Consortium Trial
• BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase
• Recent events

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/xnqo0d.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900